Introduction: Sickle cell anaemia is an autosomal recessive inherited haemoglobin disorder caused by the presence of high concentrations of abnormal haemoglobin, haemoglobin S, in the red blood cell. Pregnancy is not contraindicated in women with sickle cell disease, but it is a high-risk situation for both mother and foetus. Observed maternal mortality varies from 0.5 to 5%. The aim of this study was to describe the management and maternal-fetal prognosis of sickle cell disease during pregnancy and childbirth. Patients and methods: This was a prospective longitudinal descriptive study conducted over 12 months (1 January to 31 December 2022) in the gynaecology-obstetrics department of the Bernard Kouchner community medical centre in Coronthie, Conakry (Guinea). Pregnant women were included following diagnostic confirmation of sickle cell disease by haemoglobin electrophoresis. Results: During the study period, 43 (8.1%) of the 533 pregnant women attending antenatal clinics met our inclusion criteria. The mean age was 27.83 years, with extremes of 16 and 40 years. Professional women were the most affected (41.8%). Primiparous women and women with no schooling represented 51.2% and 39.5% of our study population respectively. The medical and obstetric history was dominated by vaso-occlusive crises (46.5%), followed by anaemia (23.2%), miscarriage (11.6%), genital infections (6.9%) and foetal death in utero (4.7%). We noted three types of sickle cell phenotype with varying proportions: the AS phenotype (65%), the SC phenotype (23%) and the SS phenotype (12%). Complications were mainly anaemia (27.9%), vaso-occlusive crises (13.9%), retroplacental haematoma (6.9%), premature rupture of membranes (6.9%), urinary tract infection (4, 6%), hypertension (2.3%), acute foetal distress (11.6%), hypotrophy (4.7), intrapartum foetal death (4.7%), in-utero foetal death (2.3%) and intrauterine growth retardation (2.3%). Conclusion: Sickle cell disease in pregnant women is common in our context and often leads to maternal and perinatal complications. The Emmel test should be performed systematically at each first antenatal consultation, along with haemoglobin electrophoresis.
Published in | Central African Journal of Public Health (Volume 9, Issue 6) |
DOI | 10.11648/j.cajph.20230906.12 |
Page(s) | 167-171 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Sickle Cell Disease, Pregnancy, Delivery, Maternal-Fetal Prognosis, Conakry
[1] | Laghdaf SM, N'Diaye AMM, Cheikh M, Heinhane MM. La Drépanocytose en Mauritanie: Aspects épidémiologiques, cliniques et thérapeutiques, à propos de 135 cas. Tunis Med. 2022; 100 (4): 313-322. |
[2] | Lambert M, Raccah-Tebeka B, Plu-Bureau G. Contraception and sickle cell disease, contraception in practice Elsevier Masson SAS 2013; chapitre 43: 194-6. |
[3] | Houndeffo T, Adisso S, Tshabu-Aguemon C, Rahimy Mc. Houssou FK, De Souza J et al. Pregnancy in sickle cell disease. Journal of the Society of Clinical Biology 2013; 018: 36-42. |
[4] | Dr Mathieu Schoeffler Anaesthesia and sickle cell disease 15th ICAR Congress, LYON, 2008 https://icarweb.fr/IMG/pdf/15-15.pdf |
[5] | Serraj K, Houda B, Hamaz S, Alaoui H, Lorenzo Villalba N, Zulfiqar AA, Andrès E. Drépanocytose et grossesse: approche pratique. mt 2019; 25 (6): 408-412. doi: 10.1684/met.2020.0824. |
[6] | Berzolla C, Seligman NS, Nnoli A, Dysart K, Baxter JK, Ballas SK. Sickle cell disease and pregnancy: does outcome depend on genotype or phenotype? International Journal of Clinical Medicine, 2011; 2 (3), 313-317. |
[7] | Ohiohin AG, Kalejaiye OO, David AN, Ohihoin EN, Herbertson EC, Gbajabiamila TA et al. Obstetric Challenges of Sickle Cell Disease in Pregnancy. Tropical Journal of Obstetrics & Gynaecology 2020; 37 (2): 2073- 278. |
[8] | Tchente CN, Brulet C, Njiengwe E, Nana TN, Tsingaing JK, Chantraine F. Antenatal diagnosis of sickle cell disease in Cameroon: the experience of the Douala antenatal diagnosis staff. Journal de la SAGO 2016: 17: 2: 33-7. |
[9] | Bonkian. C Drépanocytose et grossesse: revue de 13 observations à la Maternité Régionale Universitaire A. PINARD; Université Henri-Poincaré, Nancy 1; 2009: 495208226: 8-19. |
[10] | Mbodji. A Identification of risk factors for maternal and foetal complications in patients with major sickle cell syndrome: 198 cases. Mémoire du diplôme d'Etat de sage-femme; université Paris Descartes- ESF Baudelocque; 2012: 2012PA05MA24: 2-10; |
[11] | Ribeil JA French-Brazilian study on pregnancy in sickle cell disease. A study by the international sickle cell disease observatory. Symposia / Clinical and Biological Transfusion 2013; 20: 261-284. |
[12] | Igala M, Bang Ntamack JA, Ledaga Lentombo LE, Assoumou Obiang P, Ngossanga Bissala PD, Meye JF. Maternal and foetal outcome of pregnancies in women with sickle cell disease in Libreville. Health Sci. Dis: 2022; 23 (5): 6-10. |
[13] | Zamané H, Kain D, Kiemtoré S, Diallo A, Valéa J, Diallo et al. Preventive exchange blood transfusion in pregnant women with Sickle Cell Disease: Maternal and Perinatal Prognosis in a Country with Limited Resources, Burkina Faso. Open Journal of Obstetrics and Gynecology 2016; 6 (6): 373-378. |
[14] | Barfield WD, Barradas DT, Manning SE, Kotelchuck M, Shapiro-Mendoza CK. Sickle cell disease and pregnancy outcome: women of African descent. Suis J Préc Med 2010; 38 (4S): S542-9. |
[15] | Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199 (2): 125. e1-5. |
APA Style
Tamba Julien, T., Daniel William Athanase, L., Maimouna, B., Souleymane, T., Moussa, C., et al. (2023). Maternal-Fetal Prognosis of Pregnancy and Childbirth in Sickle-Cell Patients at the Bernard Kouchner Community Medical Centre of Coronthie in Conakry (Guinea). Central African Journal of Public Health, 9(6), 167-171. https://doi.org/10.11648/j.cajph.20230906.12
ACS Style
Tamba Julien, T.; Daniel William Athanase, L.; Maimouna, B.; Souleymane, T.; Moussa, C., et al. Maternal-Fetal Prognosis of Pregnancy and Childbirth in Sickle-Cell Patients at the Bernard Kouchner Community Medical Centre of Coronthie in Conakry (Guinea). Cent. Afr. J. Public Health 2023, 9(6), 167-171. doi: 10.11648/j.cajph.20230906.12
AMA Style
Tamba Julien T, Daniel William Athanase L, Maimouna B, Souleymane T, Moussa C, et al. Maternal-Fetal Prognosis of Pregnancy and Childbirth in Sickle-Cell Patients at the Bernard Kouchner Community Medical Centre of Coronthie in Conakry (Guinea). Cent Afr J Public Health. 2023;9(6):167-171. doi: 10.11648/j.cajph.20230906.12
@article{10.11648/j.cajph.20230906.12, author = {Tolno Tamba Julien and Leno Daniel William Athanase and Balde Maimouna and Toure Souleymane and Camara Moussa and Tolno Pascal and Bangoura Salematou and Diallo Abdourahamane and Sy Telly and Hyjazi Yolande and Keita Namory}, title = {Maternal-Fetal Prognosis of Pregnancy and Childbirth in Sickle-Cell Patients at the Bernard Kouchner Community Medical Centre of Coronthie in Conakry (Guinea)}, journal = {Central African Journal of Public Health}, volume = {9}, number = {6}, pages = {167-171}, doi = {10.11648/j.cajph.20230906.12}, url = {https://doi.org/10.11648/j.cajph.20230906.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20230906.12}, abstract = {Introduction: Sickle cell anaemia is an autosomal recessive inherited haemoglobin disorder caused by the presence of high concentrations of abnormal haemoglobin, haemoglobin S, in the red blood cell. Pregnancy is not contraindicated in women with sickle cell disease, but it is a high-risk situation for both mother and foetus. Observed maternal mortality varies from 0.5 to 5%. The aim of this study was to describe the management and maternal-fetal prognosis of sickle cell disease during pregnancy and childbirth. Patients and methods: This was a prospective longitudinal descriptive study conducted over 12 months (1 January to 31 December 2022) in the gynaecology-obstetrics department of the Bernard Kouchner community medical centre in Coronthie, Conakry (Guinea). Pregnant women were included following diagnostic confirmation of sickle cell disease by haemoglobin electrophoresis. Results: During the study period, 43 (8.1%) of the 533 pregnant women attending antenatal clinics met our inclusion criteria. The mean age was 27.83 years, with extremes of 16 and 40 years. Professional women were the most affected (41.8%). Primiparous women and women with no schooling represented 51.2% and 39.5% of our study population respectively. The medical and obstetric history was dominated by vaso-occlusive crises (46.5%), followed by anaemia (23.2%), miscarriage (11.6%), genital infections (6.9%) and foetal death in utero (4.7%). We noted three types of sickle cell phenotype with varying proportions: the AS phenotype (65%), the SC phenotype (23%) and the SS phenotype (12%). Complications were mainly anaemia (27.9%), vaso-occlusive crises (13.9%), retroplacental haematoma (6.9%), premature rupture of membranes (6.9%), urinary tract infection (4, 6%), hypertension (2.3%), acute foetal distress (11.6%), hypotrophy (4.7), intrapartum foetal death (4.7%), in-utero foetal death (2.3%) and intrauterine growth retardation (2.3%). Conclusion: Sickle cell disease in pregnant women is common in our context and often leads to maternal and perinatal complications. The Emmel test should be performed systematically at each first antenatal consultation, along with haemoglobin electrophoresis. }, year = {2023} }
TY - JOUR T1 - Maternal-Fetal Prognosis of Pregnancy and Childbirth in Sickle-Cell Patients at the Bernard Kouchner Community Medical Centre of Coronthie in Conakry (Guinea) AU - Tolno Tamba Julien AU - Leno Daniel William Athanase AU - Balde Maimouna AU - Toure Souleymane AU - Camara Moussa AU - Tolno Pascal AU - Bangoura Salematou AU - Diallo Abdourahamane AU - Sy Telly AU - Hyjazi Yolande AU - Keita Namory Y1 - 2023/12/11 PY - 2023 N1 - https://doi.org/10.11648/j.cajph.20230906.12 DO - 10.11648/j.cajph.20230906.12 T2 - Central African Journal of Public Health JF - Central African Journal of Public Health JO - Central African Journal of Public Health SP - 167 EP - 171 PB - Science Publishing Group SN - 2575-5781 UR - https://doi.org/10.11648/j.cajph.20230906.12 AB - Introduction: Sickle cell anaemia is an autosomal recessive inherited haemoglobin disorder caused by the presence of high concentrations of abnormal haemoglobin, haemoglobin S, in the red blood cell. Pregnancy is not contraindicated in women with sickle cell disease, but it is a high-risk situation for both mother and foetus. Observed maternal mortality varies from 0.5 to 5%. The aim of this study was to describe the management and maternal-fetal prognosis of sickle cell disease during pregnancy and childbirth. Patients and methods: This was a prospective longitudinal descriptive study conducted over 12 months (1 January to 31 December 2022) in the gynaecology-obstetrics department of the Bernard Kouchner community medical centre in Coronthie, Conakry (Guinea). Pregnant women were included following diagnostic confirmation of sickle cell disease by haemoglobin electrophoresis. Results: During the study period, 43 (8.1%) of the 533 pregnant women attending antenatal clinics met our inclusion criteria. The mean age was 27.83 years, with extremes of 16 and 40 years. Professional women were the most affected (41.8%). Primiparous women and women with no schooling represented 51.2% and 39.5% of our study population respectively. The medical and obstetric history was dominated by vaso-occlusive crises (46.5%), followed by anaemia (23.2%), miscarriage (11.6%), genital infections (6.9%) and foetal death in utero (4.7%). We noted three types of sickle cell phenotype with varying proportions: the AS phenotype (65%), the SC phenotype (23%) and the SS phenotype (12%). Complications were mainly anaemia (27.9%), vaso-occlusive crises (13.9%), retroplacental haematoma (6.9%), premature rupture of membranes (6.9%), urinary tract infection (4, 6%), hypertension (2.3%), acute foetal distress (11.6%), hypotrophy (4.7), intrapartum foetal death (4.7%), in-utero foetal death (2.3%) and intrauterine growth retardation (2.3%). Conclusion: Sickle cell disease in pregnant women is common in our context and often leads to maternal and perinatal complications. The Emmel test should be performed systematically at each first antenatal consultation, along with haemoglobin electrophoresis. VL - 9 IS - 6 ER -